Your Road to Wellness

Lipoic EF

One of the main benefits of alpha lipoic acid is its ability to protect the nervous system. Research has shown improved symptoms of neuropathy from taking alpha lipoic acid. It is also an effective antioxidant.

Alpha lipoic acid is a coenzyme involved in carbohydrate metabolism and production of ATP (adenosine triphosphate). Lipoic acid is an effective antioxidant that savage free radicals both intra and extra cellular (Packer L, et al. 1995). It is both fat and water soluble and can regenerate antioxidants such as vitamin e, c and glutathione preventing oxidative damage.

Lipoic acid is absorbed quickly, but it is also removed quickly by the liver. For lipoic acid to be effective, it needs to reach the tissue it is supposed to protect. Most studies have used a fast release form which is what you find in Lipoic EF. The most commonly used dosage has been 600 mg once or twice daily, which is the same as 2 tablets of Lipoic EF once or twice daily. This dosage allows more of the lipoic acid to reach the target tissue for better results.




Provides neurological benefits (Liu J. 2008).

Lipoic EF is an effective, fast release alpha lipoic-acid formula.

Research has documented that in diabetic patient’s lipoic acid improves insulin sensitivity and glucose disposal after four weeks (Konrad T, et al. 1999Jacob S, et al. 1999).

In cases of neuropathy 600 – 1200 mg per day of lipoic acid has been documented to improve symptoms such as burning, numbness, and pain. It has also shown to improve objective measurements of neurological deficit and disability within 3-5 weeks (Ruhnau KJ, et al. 1999).

Patients with sciatic pain caused by a herniated disc have shown improvements in symptoms and improvement in neuropathy on electromyography when using 600 mg of lipoic acid daily (Memeo A, Loiero M, 2008).

600 mg of alpha-lipoic acid and 360 mg of GLA have been documented to improve symptoms and electro-myography readings in patients with moderately severe carpal tunnel syndrome (Di Geronimo G, et al. 2009).

A researcher at the University of California listed the following neurological benefits of lipoic acid: Improvement of the age-associated decline in memory, improvement of mitochondrial structure and function, inhibition of age-associated increase of oxidative damage, elevation of the levels of antioxidants and restoration of the activity of key enzymes (Liu J, 2008).

Several studies have been published on the benefits of alpha lipoic acid and different forms of neuropathies. Most research has used a dosage 600 mg of alpha lipoic acid taken once a day, that’s equivalent to two tablets of the Lipoic EF taken at the same time once daily.




Nutritional Facts
Serving Size: 1 Tablet
Servings Per Container: 60

Alpha-Lipoic Acid………………………………………………………………………………………..300 mg



Di Geronimo D, Caccase AF, Caruso L, Soldati A, Passaretti U. Treatment of carpal tunnel syndrome with alpha-lipoic acid. Eur Rev Med Pharmacol Sci. 2009 Mar-Apr;13(2):133-9.
Jacob S, et al. Oral administration of RAC-alpha-lipoic acid modulates insulin sensitivity in patients with type-2 diabetes mellitus: a placebo-controlled pilot trial. Free Radic Biol Med. 1999 Aud;27(3-4):309-14.
Konrad T, et al. Alpha-lipoic acid treatment decreases serum lactate and pyruvate concentrations and improves glucose effectiveness in lean and obese patients with type 2 diabetes. Diabetes Care. 1999 Feb;22(2):280-7.
Liu J. The effects and mechanisms of mitochondrial nutrient alpha-lipoic acid on improving age-associated mitochondrial and cognitive dysfunction: an overview. 2008 Jan:33(1):194-203.
Memeo A, Loiero M. Thioctic Acid and acetyl-L-carnitine in the treatment of sciatic pain caused by herniated disc: a randomized, double-blind, comparative study. Clin Drug Investig. 2008;28(8):495-500.
Packer L, et al. Alpha-lipoic acid as a biological antioxidant. Free Radic Biol Med. 1995 Aug;19(2):227-50.
Ruhnau KJ, et al. Effects of 3-week oral treatment with the antioxidant thioctic acid (alpha-lipoic acid) in symptomatic diabetic polyneuropathy. Diabet Med. 1999 Dec:16(12):1040-3.